Literature DB >> 21404064

Comparative evaluation of immunization with recombinant protein and plasmid DNA vaccines of fusion antigen ROP2 and SAG1 from Toxoplasma gondii in mice: cellular and humoral immune responses.

Wen-Shu Li1, Qing-Xin Chen, Ju-Xiu Ye, Zi-Xin Xie, Jun Chen, Li-Fang Zhang.   

Abstract

The aim of this work was to evaluate immune responses in BALB/c mice vaccinated subcutaneously by recombinant protein, or intramuscularly by plasmid DNA with fusion antigen of rhoptry protein 2 (ROP2) and major surface protein 1 (SAG1) from Toxoplasma gondii (T. gondii). BALB/c mice were immunized with one of three different antigen formulations respectively, which were rROP2-SAG1, pcROP2-SAG1, and pcROP2-SAG1 boosted with rROP2-SAG1. The production of IgG, IgG subclasses, lymphoproliferation, and level of gamma interferon (IFN-γ) were detected after vaccination. The animals vaccinated with rROP2-SAG1 quickly developed specific anti-TLA (T. gondii lysate antigen) antibodies, which continued to rise after immunization. However, production of IgG against TLA in mice vaccinated with pcROP2-SAG1 was relatively slow and maintained a high level after reaching plateau. There are more vigorous specific lymphoproliferative responses observed in mice of group rROP2-SAG1 than in pcROP2-SAG1. Immune responses in mice of group pcROP2-SAG1 boosted with rROP2-SAG1 were similar to the protein immunization group. Three immunization procedures resulted in a similar level of IFN-γ production. Our results indicate that BALB/c mice vaccinated by three immunization procedures induce similar humoral and cellular immunity against infection of T. gondii. Mice immunized with recombinant protein rROP2-SAG1 produce more humoral immune responses than mice immunized with other antigen formulations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21404064     DOI: 10.1007/s00436-011-2296-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  26 in total

1.  Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents.

Authors:  C W Angus; D Klivington-Evans; J P Dubey; J A Kovacs
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

2.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis.

Authors:  M M Liu; Z G Yuan; G H Peng; D H Zhou; X H He; C Yan; C C Yin; Y He; R Q Lin; H Q Song; X Q Zhu
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

4.  Chimeric antigens of Toxoplasma gondii: toward standardization of toxoplasmosis serodiagnosis using recombinant products.

Authors:  Elisa Beghetto; Andrea Spadoni; Luca Bruno; Wilma Buffolano; Nicola Gargano
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 5.  [The vaccines against toxoplasmosis--current status of the studies].

Authors:  Henryka Długońska; Justyna Gatkowska; Józef Kur; Artur Gasior
Journal:  Wiad Parazytol       Date:  2007

Review 6.  Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.

Authors:  E A Innes; A N Vermeulen
Journal:  Parasitology       Date:  2006       Impact factor: 3.234

7.  Epitopes recognized by human T lymphocytes in the ROP2 protein antigen of Toxoplasma gondii.

Authors:  R Saavedra; M A Becerril; C Dubeaux; R Lippens; M J De Vos; P Hérion; A Bollen
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

8.  [Cloning and expression of the fused gene of rhoptry protein ROP2 and major surface protein P30 from Toxoplasma gondii].

Authors:  Wen-shu Li; Hui-min Lu; Tai-shan Min; Wei-da Huang
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2005-12-30

Review 9.  HIV vaccine development.

Authors:  David I Watkins
Journal:  Top HIV Med       Date:  2010 Apr-May

Review 10.  Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection.

Authors:  E Y Denkers; R T Gazzinelli
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more
  6 in total

1.  Molecular cloning, sequencing, and biological characterization of GRA4 gene of Toxoplasma gondii.

Authors:  Hira Ram; J R Rao; A K Tewari; P S Banerjee; A K Sharma
Journal:  Parasitol Res       Date:  2013-04-10       Impact factor: 2.289

Review 2.  Vaccines against a Major Cause of Abortion in Cattle, Neospora caninum Infection.

Authors:  Thierry Monney; Karim Debache; Andrew Hemphill
Journal:  Animals (Basel)       Date:  2011-09-08       Impact factor: 2.752

Review 3.  Toxoplasma gondii vaccine candidates: a concise review.

Authors:  Amirreza Javadi Mamaghani; Anwar Fathollahi; Zahra Arab-Mazar; Kobra Kohansal; Matin Fathollahi; Adel Spotin; Homayoon Bashiri; Arezoo Bozorgomid
Journal:  Ir J Med Sci       Date:  2022-04-08       Impact factor: 1.568

4.  Multicomponent DNA vaccine-encoding Toxoplasma gondii GRA1 and SAG1 primes: anti-Toxoplasma immune response in mice.

Authors:  Xiao-Nan Wu; Jie Lin; Xu Lin; Jie Chen; Zhong-Long Chen; Jian-Yin Lin
Journal:  Parasitol Res       Date:  2012-07-27       Impact factor: 2.289

5.  Identification of Antigenic and Immunogenic Proteins of Toxoplasma gondii in Human and Sheep by Immunoproteomics.

Authors:  Mohammad Taghi Ahady; Nasser Hoghooghi-Rad; Rasool Madani; Ahmad Reza Esmaeili Rastaghi
Journal:  Iran J Parasitol       Date:  2018 Jan-Mar       Impact factor: 1.012

6.  Immune responses and protection after DNA vaccination against Toxoplasma gondii calcium-dependent protein kinase 2 (TgCDPK2).

Authors:  Kai Chen; Jin-Lei Wang; Si-Yang Huang; Wen-Bin Yang; Wei-Ning Zhu; Xing-Quan Zhu
Journal:  Parasite       Date:  2017-11-09       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.